The University of Southampton
University of Southampton Institutional Repository

Omalizumab, a novel anti-IgE therapy in allergic disorders

Omalizumab, a novel anti-IgE therapy in allergic disorders
Omalizumab, a novel anti-IgE therapy in allergic disorders
The incidence of allergic diseases is increasing to epidemic proportions both in the developed and developing world with increasing medical costs and lost productivity. The discovery of immunoglobulin (Ig) E heralded a new era in pathophysiological understanding of allergic disorders. Twenty-five years later, a humanised, non-anaphylactogenic antibody was developed against IgE that could provide a therapeutic alternative to the existing medications. RhuMAb-E25 (omalizumab, Xolair®, Genetech, Inc.) is a novel anti-IgE antibody that is directed against the receptor-binding domain of IgE. This binding is specific towards free IgE thereby preventing it from attaching to the mast cell and its subsequent activation. Initial studies demonstrated attenuation of the early and late asthmatic responses when anti-IgE was administered to asthmatic subjects. Later this novel molecule was found to improve symptom scores, rescue medication use, quality of life scores and peak expiratory flows in patients with allergic asthma. Most importantly, omalizumab treatment reduced the corticosteroid use in asthmatic individuals. In patients with seasonal allergic rhinitis, there was a significant reduction in the nasal and ocular symptoms as well as the use of rescue medications. Omalizumab also demonstrated a high level of safety in adults, adolescents and children with a side effect profile no different from the placebo. Its development is an exciting milestone in the treatment of allergic diseases.
1471-2598
1049-1058
Babu, K. Suresh
abf81db8-ccac-40e0-94b7-d5c9b7049ffa
Holgate, Stephen T.
2938f54c-8823-452a-a2d3-acd0cc38663d
Arshad, S. Hasan
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Babu, K. Suresh
abf81db8-ccac-40e0-94b7-d5c9b7049ffa
Holgate, Stephen T.
2938f54c-8823-452a-a2d3-acd0cc38663d
Arshad, S. Hasan
2e7c17a9-6796-436e-8772-1fe6d2ac5edc

Babu, K. Suresh, Holgate, Stephen T. and Arshad, S. Hasan (2001) Omalizumab, a novel anti-IgE therapy in allergic disorders. Expert Opinion on Biological Therapy, 1 (6), 1049-1058. (doi:10.1517/14712598.1.6.1049).

Record type: Article

Abstract

The incidence of allergic diseases is increasing to epidemic proportions both in the developed and developing world with increasing medical costs and lost productivity. The discovery of immunoglobulin (Ig) E heralded a new era in pathophysiological understanding of allergic disorders. Twenty-five years later, a humanised, non-anaphylactogenic antibody was developed against IgE that could provide a therapeutic alternative to the existing medications. RhuMAb-E25 (omalizumab, Xolair®, Genetech, Inc.) is a novel anti-IgE antibody that is directed against the receptor-binding domain of IgE. This binding is specific towards free IgE thereby preventing it from attaching to the mast cell and its subsequent activation. Initial studies demonstrated attenuation of the early and late asthmatic responses when anti-IgE was administered to asthmatic subjects. Later this novel molecule was found to improve symptom scores, rescue medication use, quality of life scores and peak expiratory flows in patients with allergic asthma. Most importantly, omalizumab treatment reduced the corticosteroid use in asthmatic individuals. In patients with seasonal allergic rhinitis, there was a significant reduction in the nasal and ocular symptoms as well as the use of rescue medications. Omalizumab also demonstrated a high level of safety in adults, adolescents and children with a side effect profile no different from the placebo. Its development is an exciting milestone in the treatment of allergic diseases.

Full text not available from this repository.

More information

Published date: 2001

Identifiers

Local EPrints ID: 26916
URI: https://eprints.soton.ac.uk/id/eprint/26916
ISSN: 1471-2598
PURE UUID: fdec8580-d7d2-4746-9555-e294748b3e0b

Catalogue record

Date deposited: 25 Apr 2006
Last modified: 15 Jul 2019 19:13

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×